Video

Dr Robert Gabbay Discusses the Importance of New CKD Section in ADA Guidelines

Author(s):

Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.

Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), explains why a section on chronic kidney disease (CKD) management was added to the ADA's 2022 standard of care guidelines.

Transcript:

What evidence led to the addition of Section 11 in the ADA’s 2022 guidelines?

Gabbay: [A couple] of the things that became clear based on some of the recent studies and new treatments that are available are a couple of things. One, we know that chronic kidney disease continues to be a huge issue and it's under-diagnosed and under-treated. And second, we now have new treatments that can really lower the risk of chronic kidney disease, and particularly the progression. So, we called out all of that information by making chronic kidney disease a separate section [of the guidelines] to emphasize the importance of it.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Martin Engelke
David Awad, PharmD, BCOP
Dr Adela Perolla
Dr Adela Perolla | Image Credit: - stock.adobe.com
Dr Ola Landgren
Dr Ola Landgren
Andrew Kuykendall, MD, Moffitt Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo